Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 9
Submit an article Journal homepage
48
Views
0
CrossRef citations to date
0
Altmetric
Theme: Heart Failure - Editorial

Heart failure with preserved ejection fraction: future directions in medical treatment

Dimitrios M Konstantinou First Department of Cardiology, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece and Heart Failure Care group, The Royal Brompton Hospital, London Imperial College, London, UK
,
Yiannis S Chatzizisis First Department of Cardiology, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece and Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA [email protected]
&
George D Giannoglou First Department of Cardiology, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece
Pages 1085-1087 | Published online: 10 Jan 2014

References

  • Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med. 355(3), 260–269 (2006).
  • Penicka M, Bartunek J, Trakalova H et al. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: a pressure-volume loop analysis. J. Am. Coll. Cardiol. 55(16), 1701–1710 (2010).
  • Mohammed SF, Borlaug BA, Roger VL et al. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ. Heart Fail. 5(6), 710–719 (2012).
  • Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circ. Heart Fail. 1(2), 91–97 (2008).
  • Mak GJ, Ledwidge MT, Watson CJ et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J. Am. Coll. Cardiol. 54(18), 1674–1682 (2009).
  • Daniel KR, Wells G, Stewart K, Moore B, Kitzman DW. Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest. Heart Fail. 15(2), 68–74 (2009).
  • Edelmann F, Wachter R, Schmidt AG et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309(8), 781–791 (2013).
  • Kruger M, Kotter S, Grutzner A et al. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ. Res. 104(1), 87–94 (2009).
  • Solomon SD, Zile M, Pieske B et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380(9851), 1387–1395 (2012).
  • Silberman GA, Fan TH, Liu H et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 121(4), 519–528 (2010).
  • Van Heerebeek L, Hamdani N, Falcao-Pires I et al. Low myocardial protein kinase g activity in heart failure with preserved ejection fraction. Circulation 126(7), 830–839 (2012).
  • Moens AL, Takimoto E, Tocchetti CG et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 117(20), 2626–2636 (2008).
  • Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124(2), 164–174 (2011).
  • Andersen MJ, Ersbøll M, Axelsson A et al. Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial. Circulation 127(11), 1200–1208 (2013).
  • Redfield MM, Chen HH, Borlaug BA et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309(12), 1268–1277 (2013).
  • Zeitz O, Maass AE, Van Nguyen P et al. Hydroxyl radical-induced acute diastolic dysfunction is due to calcium overload via reverse-mode Na(+)-Ca(2+) exchange. Circ. Res. 90(9), 988–995 (2002).
  • Lacombe VA, Viatchenko-Karpinski S, Terentyev D et al. Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293(5), R1787–1797 (2007).
  • Maier LS, Layug B, Karwatowska-Prokopczuk E et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: The RALI-DHF proof-of-concept study. JCHF 1(2), 115–122 (2013).
  • Kamimura D, Ohtani T, Sakata Y et al. Ca2+ entry mode of Na+/Ca2+ exchanger as a new therapeutic target for heart failure with preserved ejection fraction. Eur. Heart J. 33(11), 1408–1416 (2012).
  • Kelly A, Elliott EB, Matsuda R, Kaneko N, Smith GL, Loughrey CM. The effect of K201 on isolated working rabbit heart mechanical function during pharmacologically induced Ca2+ overload. Br. J. Pharmacol. 165(4b), 1068–1083 (2012).
  • Kaneko N, Matsuda R, Ohtani N et al. K201 Improves norepinephrine-induced diastolic dysfunction with preserved ejection fraction. Drug Develop. Res. 67(11), 852–861 (2006).
  • Diamant M, Lamb HJ, Groeneveld Y et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled Type 2 diabetes mellitus. J. Am. Coll. Cardiol. 42(2), 328–335 (2003).
  • Abozguia K, Elliott P, McKenna W et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122(16), 1562–1569 (2010).
  • Von Bibra H, Diamant M, Scheffer PG, Siegmund T, Schumm-Draeger PM. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in Type 2 diabetic patients without overt heart disease. Diab. Vasc. Dis. Res. 5(4), 310–318 (2008).
  • Van Der Meer RW, Rijzewijk LJ, De Jong HW et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 119(15), 2069–2077 (2009).
  • Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation 117(4), 574–584 (2008).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.